Mankind Pharma
 | A major contributor to this article appears to have a close connection with its subject. (June 2015) |
| File:Mankind1.png | |
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1995 |
| Founder | R_C_Juneja, Rajeev Juneja |
| Headquarters | , |
Key people | Arjun Juneja, Sheetal Arora, Sanjay Koul |
| Products | Pharmaceuticals, Generic drugs, OTC, FMCG, Diagnostics |
| Revenue | INR 6000 Crores FY20 |
Number of employees | 16000+ |
| Subsidiaries | Lifestar, Magnet |
| Website | www |
Mankind Pharma is a pharmaceutical company in India based at New Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. They are covering Industrial sectores in Pharmaceuticals, Medical Research & Laboratories domain. Mankind Pharma Ltd is a public company.
Mankind Pharma was formed in 1991. It started working as a fully integrated pharmaceutical company in 1995 with the contributions of two brothers, R C Juneja and Rajeev Juneja. The seed capital for establishing the company was 50 Lakh.[1] The company was started with 20 employees and launched in two states in the 1st year of its operation.[2]
In 2019, Mankind became the 1st Indian company and 2nd only in the world to develop and launch Dydrogesterone, a drug used in high risk pregnancies by the brand name Dydroboon. The company acquired Magnet Labs Pvt. Ltd. to enter the antipsychotic segment in 2007.[3] Also it acquired Longifene-an appetite stimulant for children, in January 2010 which was earlier a brand of UCB Belgium.[4]
References
- ^ Hussain, Shabana (8 May 2014). "Mankind Pharma: Formulating Strategy To Enter The Big League". Retrieved 27 June 2018.
- ^ "A Giant Leap For Mankind". Business Outlook India. 24 December 2011. Archived from the original on 29 June 2012. Retrieved 5 February 2013.
- ^ Acquisition of Magnet Labs[permanent dead link]
- ^ Mankind Pharma markets Longifene- 29 August 2011